• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Cascade Investment, L.L.C. claimed ownership of 151,865,481 units of Class A Common Stock

    9/24/21 4:24:22 PM ET
    $SRNG
    Get the next $SRNG alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    CASCADE INVESTMENT, L.L.C.

    (Last) (First) (Middle)
    2365 CARILLON POINT

    (Street)
    KIRKLAND WA 98033

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    09/16/2021
    3. Issuer Name and Ticker or Trading Symbol
    Ginkgo Bioworks Holdings, Inc. [ DNA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Class A Common Stock 151,865,481(1) D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    CASCADE INVESTMENT, L.L.C.

    (Last) (First) (Middle)
    2365 CARILLON POINT

    (Street)
    KIRKLAND WA 98033

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    GATES WILLIAM H III

    (Last) (First) (Middle)
    2365 CARILLON POINT

    (Street)
    KIRKLAND WA 98033

    (City) (State) (Zip)
    Explanation of Responses:
    1. Includes 15,949,483 earn-out shares that will vest in four substantially equal installments if the issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $12.50, $15.00, $17.50 and $20.00.
    Remarks:
    Exhibit List: Exhibit 24.1 - Power of Attorney (Cascade Investment, L.L.C.); Exhibit 24.2 - Power of Attorney (William H. Gates III)
    Cascade Investment, L.L.C. By: /s/ Alan Heuberger, Attorney-in-fact for Michael Larson, Business Manager 09/24/2021
    William H. Gates III By: /s/ Alan Heuberger, Attorney-in-fact 09/24/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SRNG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRNG

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SRNG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ginkgo Bioworks to Go Public with Over $1.6 Billion in Proceeds

    Soaring Eagle Shareholder Approval Obtained, Closing Scheduled for September 16, 2021 Ginkgo Set to Begin Trading under NYSE: DNA on September 17, 2021 $1.633 billion in proceeds from the business combination represents the largest-ever biotechnology go-public transaction. Investors were led by Baillie Gifford, Putnam Investments, and funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management). Additional investors included ARK Investment Management LLC, ArrowMark Partners, Bain Capital Public Equity, Cascade Investment, Casdin Capital, Franklin Advisers, T. Rowe Price, and Viking Global Investors. Business combination with Ginkgo approved by Soaring Eagl

    9/14/21 9:13:00 AM ET
    $SRNG

    Africa CDC and Ginkgo Bioworks Announce Collaboration to Strengthen Laboratory Network Capacity Across African Union Member States

    BOSTON and ADDIS ABABA, Ethiopia, Sept. 14, 2021 /PRNewswire/ -- The Africa Centres for Disease Control and Prevention (Africa CDC), a specialized technical institution of the African Union, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to bolster the laboratory network capacity for African Union Member States. The partnership is aimed at supporting the continent's public health institutions with appropriate tools, training, and data infrastructure to leverage critical genomic sequencing technologies that will be implemented through Africa CDC Institute for Pathogen Genomics (IPG) and Ginkgo Bioworks.  Gin

    9/14/21 7:58:00 AM ET
    $SRNG

    Concentric by Ginkgo Stands Ready to Continue Fighting Pandemic, Providing Biosecurity and COVID Testing Nationwide to Schools, Workplaces, and Other Congregate Settings

    BOSTON, Sept. 10, 2021 /PRNewswire/ -- Ginkgo Bioworks ("Ginkgo"), which is building the leading horizontal platform for cell programming, today announced its readiness to continue scaling support for COVID testing in congregate settings in response to new emergency standards and recommendations issued by the Biden-Harris Administration. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), serves customers across industries seeking to develop new and better products using biology. Last year, Ginkgo launched Concentric by Ginkgo, its public health and biosecurity initiative, to provide a response to the COVID-19 pandemic. Since then, Conc

    9/10/21 3:00:00 PM ET
    $SRNG

    $SRNG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: New insider Cascade Investment, L.L.C. claimed ownership of 151,865,481 units of Class A Common Stock

    3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    9/24/21 4:24:22 PM ET
    $SRNG

    SEC Form 3: New insider Viking Global Investors Lp claimed ownership of 339,055,144 units of Class A Common Stock

    3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    9/23/21 4:11:12 PM ET
    $SRNG

    SEC Form 4: Eagle Equity Partners Iii, Llc returned 11,534,052 units of Class A Common Stock to the company, decreasing direct ownership by 27% to 31,590,948 units

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    9/22/21 9:57:03 PM ET
    $SRNG

    $SRNG
    SEC Filings

    View All

    SEC Form EFFECT filed by Soaring Eagle Acquisition Corp.

    EFFECT - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    9/21/21 12:15:16 AM ET
    $SRNG

    SEC Form 424B3 filed by Soaring Eagle Acquisition Corp.

    424B3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    9/20/21 5:24:23 PM ET
    $SRNG

    Soaring Eagle Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Material Modification to Rights of Security Holders, Other Events, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status

    8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    9/20/21 5:19:07 PM ET
    $SRNG

    $SRNG
    Financials

    Live finance-specific insights

    View All

    Ginkgo Bioworks Announces Date of First Half 2021 Results Presentation

    BOSTON, Aug. 9, 2021 /PRNewswire/ -- Ginkgo Bioworks, Inc. ("Ginkgo"), which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), announced that it will host a presentation reviewing results for the first six months of 2021 after the market closes on Wednesday, August 18, 2021, beginning at 4:30 p.m. ET. The presentation will include an overview of first half performance, recent updates, and a discussion on Ginkgo's business model and outlook. The presentation details and registration link will be available on Ginkgo's investor relation

    8/9/21 7:00:00 AM ET
    $SRNG

    $SRNG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Soaring Eagle Acquisition Corp. (Amendment)

    SC 13D/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    10/1/21 5:02:37 PM ET
    $SRNG

    SEC Form SC 13G filed by Soaring Eagle Acquisition Corp.

    SC 13G - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    9/28/21 4:31:04 PM ET
    $SRNG

    SEC Form SC 13G filed by Soaring Eagle Acquisition Corp.

    SC 13G - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    9/27/21 5:29:26 PM ET
    $SRNG